gsk responsible business supplement image hiv virus gsk responsible business supplement supplement commercially successful content cover image operate responsibly statement lynn elsenhans chair gsk dolutegravirbase medicine provide muchneede treatment improve people health corporate responsibility committee option people live hiv find emma walmsley chief executive officer create value shareholder support access dolutegravir society approach responsible business brazil botswana medicine patent pool report provide performance update benchmark external perspective responsible business commitment independent commentary aron cramer key area health behaviour people president ceo bsr planet overview information report supplemental highlight month information gsk annual report health develop innovative product improve access healthcare patient consumer world behaviour embed value business include way research develop sell market product people create inspire supportive work environment encourage employee develop capability achieve good planet manage environmental impact operation product lifecycle reduce carbon emission water use waste engage stakeholder example engage key stakeholder group datum summary key datum gsk responsible business supplement committee chairmans statement ceo statement global healthcare company expectation great honour lead gsk like thank lynn stakeholder gsk deliver longterm value leadership chair corporate responsibility committee shareholder society company contribution oversee responsibility deliver longterm value society meeting societys challenge scrutinise please introduce responsible business supplement challenge meet expectation remain company important purpose help people strategic importance company chair corporate feel well live long long history tackle responsibility committee fellow committee world big health challenge know important member support board assess company employee certainly important joined operating way seeks meet expectation company commitment improve global health extent embed strategy great later year responsible business continue leadership committee work emma team challenge progress launch new investor patient consumer employee community shape gsk responsible business agenda key focus commitment set year review activity support company new set focus long rightly expect company consider social impact financial impact seek create value long term year ago longterm priority innovation performance trust include term commitment start role take opportunity understand global health environment health safety issue build trust demonstrate view broad range stakeholder feedback receive partner customer society critical sustainable play big development new balanced set business enable gsk continue create value deliver continue commitment longterm priority gsk innovation performance trust wide economic benefit society deliver societal value invest deliver financial return broad role committee close eye evolve longterm societal contribution view company key stakeholder committee hold later year launch new set focused longterm discussion trend stakeholder expectation likely commitment demonstrate continue commitment deliver influence trust performance gsk long term societal value big impact use scientific pleased note investor increasingly look technical knowhow address global health need like hiv incorporate environmental social governance esg factor malaria need support sustainable access highquality alongside traditional financial analysis determine longterm product responsible business modern value company committee believe esg issue employer practice support talented people well strong factor longterm company success fully support independent benchmarking important pleased direction travel year performance recognise improved role committee include monitor company effort position dow jones sustainability index achievement engage effectively key stakeholder welcome lead industry access vaccine index enhance content stakeholder engagement supplement antimicrobial resistance benchmark number position welcome external insight aron cramer alltrial transparency index clinical trial report course president ceo bsr possible hard work employee partner grateful effort look forward work great progress commitment set year ago document set performance company position transition new target later support longterm strategic trust priority emma walmsley chief executive officer lynn elsenhans chair gsk corporate responsibility committee gsk responsible business supplement approach responsible business approach responsible business support purpose help people feel well live long progress look forward focus impact investor patient consumer employee communitie responsible business supplement report progress give new longterm priority work year expect company consider social environmental set commitment focus area embed responsible business practice operation financial impact seek create value long term set year ago direction set global goal later year launch new set commitment describe action help approach responsible business support purpose help commitment complete progress deliver societal value earn trust seek establish people feel well live long focus research track work need work clear ambitious target drive impact progress area develop extend access medicine vaccine consumer deliver commitment embed healthcare product improve people life strive run everyday business practice operation address global health need science business responsibly ethically invest people protect new longterm priority create sustainable access highquality product environment help million people announce new company goal world world support global goal health creating value responsible business modern employer practice innovative good performing trust healthcare shareholder support longterm success business company alongside goal introduce new long continue seek transparent trust engagement governance term priority company innovation performance trust scientific medical community address environmental impact responsible business activity oversee boardlevel maintain ethical standard conduct business corporate responsibility committee crc management key work area cover report continue risk oversee audit risk committee current commitment mark complete innovation crc chair nonexecutive director lynn elsenhans business usual contribute directly meet time year discuss external issue impact new target operating principle mean set business reputation provide strategic guidance review commitment cover report reframe performance ceo chairman attend meeting performance new target specifically focus area integrate year committee focus support new target phase activity review company proposal future responsible business complete andor long priority publish activity support company new longterm priority trust new set target provide detailed analysis trust gsk responsible business supplement benchmark external perspective reporting commentary aron cramer external benchmarking president ceo bsr gsk top access medicine index biennial assessment begin like commend gsk responsible area supplement lead industry business supplement strengthen include access vaccine index please supplement begin clear wellconceive overall welcome insight gsk collective anti microbial resistance statement purpose ceo emma walmsley lynn elsenhans challenge face addressing issue supplement benchmark early chair board committee letter clear supplement correctly provide report gsk achievement companys essential purpose approach link hugely valuable touch progress need improve rank heartening include review company purpose barrier present challenge second industry dow jones priorities wellreflecte report specifically supplement speak gsk commitment sustainability world europe index place respect gsk new trust priority company building healthcare infrastructure context sector economic environmental stake important territory commitment responsible challenge associate valuable contribution social performance enterprise modern employer practice time public understand crucial issue nature availability quality employment undergo transformative insight approach sale adopt change increasingly important dimension corporate highly valuable give gsk leadership issue responsibility positive call area focus gsk rank guardian additional analysis new approach work graduate employer gsk strong performance commitment cover contribution broad understand issue time graduate supplement positive company look ahead encourage employer section work party enhance gsk ambitious adopt new target progress overview common issue identify require sustainable development goal depend large follow action extensive review gsk conduct leadership private sector time public sector leader part world face political challenge finally section engage stakeholder ftsegood index benchmark strengthen information provide picture additional specific element supplement merit positive attention company base environmental stakeholder view perspective gsk action social governance esg practice gsk achievement transparency clinical trial strong point greatly appreciate opportunity review supplement gsk member good recognize party assessment present independent view convey company similarly inclusion section approach tax tax objective performance authority extremely welcome company include award grade important topic report cdps climate change programme gsk performance diversity inclusion topic global company rightly receive considerable attention strong recognise company employee engagement figure appear demonstrate respond survey aron cramer business value effort president ceo bsr achieve score cdps water programme second year run company achieve recognition gsk responsible business supplement overview year significant progress health develop treatment reduce child training health address cold tackle antimicrobial neglect tropical hiv mortality worker chain challenge resistance disease receive fda approval reach million achieve goal new design synflorix train end juluca drug regimen child country year early reach million vaccine mean last day healthcare professional donate nearly billion daily single pill treatment lifesaving intervention underserve people open hour responsible use antibiotic albendazole tablet prevent hiv potential begin training mean clinic pharmaceutical pipeline lymphatic filariasis intestinal significant difference live fiveyear partnership frontline health worker healthworker able gepotidacin new worm people live hiv save child vaccinate child vial class antibiotic read behaviour people planet transparent work employee inclusive workplace carbon emission water use clinical trial party engagement rank party oversight engagement level rank cut operational carbon water alltrial transparency index programme successfully increase significantly stonewall workplace equality emission build longstanding roll global employee survey index list total value chain emission water commitment transparency party track employee proud work lgbt inclusive rise extend access clinical trial reach early gsk recommend employer medicine great place work work address read read read gsk responsible business supplement progress summary report cover progress set commitment set year ago later publish new set commitment drive impact progress health behaviour tackle big global health challenge promote open innovation value patient focus transparency respect integrity underpin make medicine vaccine accessible strengthen healthcare system commitment progress tracker commitment progress tracker innovation unmet medical need complete ethical conduct progress well access medicine vaccine complete promote value sale marketing practice complete building product well meet need complete transparency clinical trial datum complete strengthen healthcare infrastructure complete rigorous patient consumer safety progressing reduce child mortality complete minimise animal testing complete fight malaria complete respect human right progress eradicate polio progress work party progress access antiretroviral treatment hiv progressing ensure ethical interaction complete eliminate control neglect tropical disease ntds progress people planet aim create safe healthy inclusive working environment able work hard minimise environmental footprint stage value inspire realise potential help succeed chain extend access product people world commitment progress tracker commitment progress tracker develop people healthy inspire workplace progress aim carbon neutral work need promote inclusion diversity progress reduce water impact progress community volunteering create change complete reduce waste track complete commitment complete progressing able demonstrate clear deliverable track work ongoing work need work need commitment schedule gsk responsible business supplement health innovation unmet medical need tackle antibiotic resistance alzheimer disease commitment adapt open innovation model extensive use misuse antibiotic mean effectiveness participate collaboration accelerate development currently disease develop world ddw wane fast major public health crisis treatment alzheimer dementia include million apply area great unmet medical need action million people die drugresistant infection dementia discovery fund dementia platform accelerate year scientific challenge include infectious disease medicine partnership continue work wellcome trust alzheimer disease neuroimmunology consortium investigate mood disorder scale task remain significant important work pharmaceutical industry government find creative way alzheimer treated target immune system incentivise reward new research development antibiotic noncommunicable disease africa vaccine play critical role avoid need antibiotic complete support researcher project subsaharan africa prevent bacterial viral infection help establish amr industry alliance coalition drive progress address increase burden noncommunicable disease ncds commitment industry davos continent africa ncd open lab declaration industry roadmap amr progress initiate new clinical research collaboration january rank large pharmaceutical lab active collaboration aim improve company access medicine foundation amr disease develop world understand nature asthma cancer cardiovascular benchmark assess pharmaceutical generic biotech open lab tre canto spain offer external scientist access kidney disease african patient project form company response amr gsk receive score expertise resource discover innovative medicine ddws collaboration medical research council south africa research area manufacturing production appropriate tre canto open lab foundation support research access stewardship project open seven new project pharmaceutical pipeline gepotidacin new class result lab lead publication paper establish collaboration open lab antibiotic expect progress phase iii clinical research peerreviewe scientific journal university witwatersrand south africa help build developed collaboration government biostatistic capacity subsaharan africa partner biomedical advanced research development authority gsk ddw centre support phase clinical trial new defense threat reduction agency candidate drug tuberculosis phase study expect begin begin latestage preclinical study promote responsible use antibiotic train healthcare professional globally management community molecule potential shorten treatment acquire respiratory tract infection appropriate usage antibiotic funding bill melinda gates foundation prescribe guideline importance surveillance study biopreparedness review antimicrobial resistance commit prepare global health threat maintain reserve capacity respond future influenza pandemic involve development universal influenza vaccine candidate number research partnership continue advance rapidresponse vaccine platform technology prepare future public health emergency healthcare professional train globally vaccine unmet global health need responsible use antibiotic gsk vaccines institute global health develop vaccine protect wide range disease include shigella invasive nontyphoidal salmonella typhoid paratyphoid fever group streptococcus participate publicprivate partnership develop vaccine hiv clinical trial underway clinical proof concept study new vaccine continue aeras nonprofit read online read online research biotech phase primary result available open innovation antibiotic resistance africa ncd open lab gsk responsible business supplement well access medicine vaccine establish contract supply synflorix mdecin improve affordability develop country commitment embed flexible pricing san frontire msf unicef low price support goal ensure work good interest strategy innovative business model immunisation programme refugee patient shareholder price new medicine prescription medicine vaccine increase usage vaccine reflect commitment establish price able access afford product supply unicef million dose aim balance reward innovation access affordability rotarix protect rotavirus gastroenteritis include dose support introduction pakistans vaccination programme negotiate payer gain medicine favourable increase supply placement formulary list product cover health complete discussion gavi unicef determine meet insurer pharmacy benefit manager patient generally future demand low outofpocket cost medicine prefer treatment formulary progress support gavi pilot cervarix vaccine human papillomavirus hpv country gsk patient assistance program provide gsk prescribe gsk equitable pricing strategy medicine vaccine supply cervarix universal mass vaccination programme medicine vaccine patient value base country disease area product type patient ability zimbabwe cervical cancer lead cause million cost good sell continue enhance pay invest community world product death woman programme easy patient use simplify cash donation global community investment gsk company commit year price freeze digital platform total million support country transition gavi finance europe engage government payer balance support affordability develop access affordability work sustainable health world intellectual property organization wipo middleincome country system support ongoing innovation international federation pharmaceutical manufacturer cap price patent medicine association ifpma launch new partnership call develop country western europe patinforme facilitate access medicine patent information long manufacturing cost cover gsk play instrumental role development partnership vaccine dose develop low catalyse commitment information middleincome country low vaccine price offer patent portfolio freely available organisation gavi vaccine alliance support early announce plan restructure pharmaceutical country gni head operation subsaharan africa improve oversight efficiency commit deliver million dose pneumococcal despite change maintain commitment address vaccine synflorix gavi discount price health challenge subsaharan africa patient access remains deliver million dose expect priority continue medicine vaccine new synflorix fourdose vial presentation available widely available region gavisupporte country dose synflorix deliver gavi read online access healthcare gsk responsible business supplement building product well meet need strengthen healthcare infrastructure reduce child mortality commitment continue build core range commitment continue work partner commitment continue invest innovative crosssector product format well meet need people support strengthen healthcare infrastructure partnership reduce child mortality globe include able access anticipate improve access healthcare afford product million underserved people complete complete complete progress progress progress successfully build new product meet medical need reinveste profit sale launch fiveyear partnership save child include new fourdose vial synflorix pharmaceutical consumer healthcare product develop ambition help save million children live world country ldc million total strengthen local poor country need vaccine medicine refrigerate major healthcare infrastructure obstacle access hot country receive positive approach end year partnership scientific opinion european medicine agency ema partnerships amref health africa care reach million child country new fourdose vial presentation synflorix pneumococcal international save child help train lifesave intervention advocate universal vaccine design specifically address cold chain challenge frontline health worker help exceed goal health coverage global national level create reduce physical space require delivery storage reach million underserved people new distribute potentially lifesave medicine prevent umbilical cord programme botswana cameroon namibia training infection chlorhexidine gel benefit receive prequalification assessment frontline health worker subsaharan africa ldc newborn gsk employee raise million international procurement agency support partnership distribution resourcelimite country subject local zambia community health entrepreneur train regulatory approval plan start supply vaccine live social enterprise establish care phase gsk save child partnership gavisupporte country international barclay reach approximately continue address child mortality launch people healthcare information entrepreneur sell clinic healthcare worker able vaccinate nearly healthcare product child vial compare exist synflorix twodose gsk product support livelihood vial presentation new formulation allow vaccine day open instead hour allow extended mvaccination pilot vodafone nigeria exist format follow request national ministry health tanzania support integrate sms reminder nearly vaccine dose administer child new presentation synflorix platform partner vodafone set vaccine help address cold chain programme lesotho use mobile technology help hivpositive child pregnant woman access treatment challenge develop country luc debruyne ilan godfrey save children president global vaccine read online read online read online give mother baby healthy start reinveste healthcare save children partnership gsk responsible business supplement fight malaria eradicating polio approve tafenoquine new treatment vivax commitment build year commitment commitment continue support objective malaria year potential important contribute fight malaria continue eradicate polio provide vaccine unicef tool malaria elimination effort support work investment partnership ground achieve partnership medicine malaria venture bill melinda gates foundation path enable patient access need complete enable use tafenoquine treat vivax malaria child progress complete study call teach assess appropriate dose childfriendly dispersible formulation progress progress invest local programme develop vaccine prevent malaria partnership comic relief support worldwide incidence polio decline rtss vaccine malaria vaccine candidate date project african country great mekong global polio eradication initiative launch year ago receive positive scientific opinion european subregion south east asia focus fight malaria despite enormous stride combat potentially debilitate medicine agency ema recommendation pilot improve health partnership aim help sure lifethreatening disease record case implementation intervention prevent diagnose treat malaria people final step completely eradicate polio prove extremely need need project range youthle follow successful phase iii trial support plan challenge goal end polio meet approach increase malaria awareness training frontline pilot malaria vaccine implementation programme subsaharan community healthcare worker volunteer project support eradication effort supply africa work path ministry tanzania ghana mozambique launch oral polio vaccine opv bivalent type health kenya ghana malawi stakeholder reach people monovalent type unicef ensure successful implementation pilot programme parallel deliver million dose opv unicef gsk prepare implementation phase programme bring billion dose deliver start manufacturing activity gsk donate million dose rtss vaccine support pilot programme subsaharan africa rtss vaccine aim protect child falciparum malaria common subsaharan africa responsible malarial death worldwide clinical trial underway dose oral polio vaccine nextgeneration vaccine preclinical study candidate deliver unicef molecule treat acute falciparum malaria develop new treatment late stage development tafenoquine single mia colli comic relief dose treatment vivax malaria common south asia horn africa latin america result phase iii trial adult present new drug application submit fda therapeutic goods administration australia seek approval use prevention relapse read online read online fight malaria unicef information polio gsk responsible business supplement access antiretroviral treatment hiv eliminate control neglect tropical disease accelerate access treatment commitment viiv healthcare continue innovative hiv drug dolutegravir available research new treatment increase access medicine commitment help eliminate control neglect brazil line treatment people live hiv care people live hiv world treatment thirdline therapy patient tropical disease ntds affect billion people support unaid deliver ambition previously treatment national health include elimination lymphatic filariasis work community combat programme dolutegravir available line treatment continued investment ongoing stigma discrimination associate hiv botswana national treat hiv programme product donation contribution london add essential medicine list russia declaration ntds follow tentative fda approval generic version dolutegravir introduce select country cover voluntary progressing licence agreement unbacke medicine patent pool progress aurobindo pharma ltd licenses enable generic formulation progress dolutegravir include fixeddose combination contain dolutegravir recommend dhh guideline progress receive fda approval juluca singletablet available generic manufacturer cover adult drug regiman dolutegravir rilpivirine maintenance child live hiv develop world gsk donate nearly billion albendazole tablet virologically supresse hiv patient follow positive phase iii include million reach million european commission fda approve reduction result regulatory submission european people intestinal worm april togo weight limit treatment hiv dolutegravir child medicine agency african country eliminate public health problem seven adolescent mean yearold eligible country achieve later year estimate juluca mark important milestone hiv care provide new receive treatment number people risk infection require mass treatment option significant difference people positive action community drug administration decrease billion people million live hiv reduce number antiretroviral continue support hiv education prevention receive lifelong treatment chronic condition viiv healthcare positive action programme positive action research ntds continue candidate molecule phase iii clinical trial begin investigational award new grant main global programme treatment visceral leishmaniasis discover collaboration twodrug treatment regimen dolutegravir plus lamivudine man sex man transgender people girl dundee university progressing clinical study cabotegravir plus rilpivirine longacte formulation woman adolescent child support community organisation europe new grant new positive begin programme phase iii study evaluate action initiative launch support woman young people longacte injectable cabotegravir prevention hiv infection highrisk population resourcepoor setting publicprivate collaboration positive action challenge work global partner find innovative solution specific press issue affect hiv epidemic postrape care girl receive fda approval emergency setting antiretroviral adherence breastfeed juluca important milestone hiv care mother address stigma healthcare setting deborah waterhouse viiv healthcare global specialist hiv company majority own gsk ceo viiv healthcare people live hiv know hiv status diagnose receive sustain antiretroviral therapy receive therapy undetectable viral load read online cover adult mpp website viiv healthcare read online positive action programme tackle ntds gsk responsible business supplement behaviour ethical conduct promote value sale marketing practice people feel confident speak run speak campaign commitment continue strengthen business raise awareness multiple valuesbase culture training people commitment continue drive valuesbased approach channel offer people outside gsk voice standard expect encourage report concern ask question independent party sale marketing practice world concern embed value way confidentially anonymously preferred receive interest consumer patient core measure employee performance report available channel review formal investigation initiate frequent category report employee performance complete progress product promotion instance past commercial practice progress bring regulatory sanction company pay large progress fine past behaviour inconsistent expectation promote valuesbased approach sale code conduct take action improve training people gsk eliminate use individual sale target control aware need constant vigilance mandatory annual training value code conduct pharmaceutical vaccine sale representative change design help employee complementary worker fraud office continue investigate group implement expand market understand value practice daily work commercial operation number country include china globally today sale representative incentivise life manage ethical dilemma encounter request additional information group base sell competency broad business performance party adviser engage company course china live value training emphasise zero tolerance approach valuesbase approach prove effective independent investigation securities exchange commission bribery corruption highlight commitment issue assessment gsk respiratory vaccine salesforce show department justice investigate matter product quality datum protection provide overview key effectiveness continue improve sale outcome refer legal proceeding note company risk employee complementary rank quartile compare peer annual report information worker complete training people priority market undergo additional training antibribery corruption help disciplinary action engage healthcare professional manage specific risk inherent role responsibilitie employee behave way align policy introduce policy stop pay hcp speak appropriate disciplinary action employee ethic compliance professional gsk prescriber prescription medicine vaccine discipline policy violation include certify skill ethic compliance academy believe policy improve transparency trust fail complete mandatory living value antibribery launch feedback scientific expert important scientific dialogue corruption training require timeframe gsk reduce intent continue assess value embed discipline employee receive document warning policy transparent scientific dialogue engagement expert specific part business value maturity receive verbal warning interest work develop new medicine assessment conduct past year individual area dismiss agree leave company voluntarily improve care patient business insight assessment continue enhance way value embed way work gsk discussion employee discipline breakdown type policy violation address feedback consult hcp guide facilitate conversation value business decide change policy allow fair market value train completion leader team widely business payment gsk expert researcher hcp code conduct report investigate concern attendancepayroll speak science product disease clinical practice limited number gsksponsore medicalle meeting want maintain open environment concern raise good manufacturing practice good distribution practice market promotional activity read online ethical conduct local work regulation continue overleaf gsk policy code standard policy violation gsk responsible business supplement promote value sale marketing practice transparency clinical trial datum continue approval sign datasharing agreement researcher commitment transparent possible believe change good interest patient access analyse data secure computer system clinical trial datum include publish clinical study help effective transparent scientific dialogue allow hcp end list trial report patientlevel datum outcome trial share new science primary focus remain wwwclinicalstudydatarequestcom internal medical expert speak product medicine conduct gsk appropriate sponsor proposal approve relate pay hcp talk product outside approve process make available researcher access gsk trial datum result research paper medicalle scientific workshop symposium anonymise patient level datum scientific enquiry publish continue effort develop plain language summary study communicate result way continue strengthen online resource inhouse readily understandable people outside scientific community medical capability provide bespoke product information hcp exist channel increase overall complete post date gsk clinical study register interaction customer digital interaction grow progress disclosing payment hcp commit disclosing payment hcp rank number alltrial transparency activity advisory board scientific symposium index clinical trial transparency index publish bmj market research help develop medicine vaccine base systematic assessment pharmaceutical meet patient need fulfil requirement european company include world large company publish federation pharmaceutical industry association efpia policy clinical trial registration reporting come disclosure code disclosing payment name individual assessment look trial registration summary result disclose aggregate basis payment relate research clinical study report individual patient level data build development longstanding commitment clinical trial transparency gsk publish payment hcp market gsk company publish clinical study europe include russia ukraine australia japan report report form basis submission regulatory late year reporting agency end report gsk longstanding commitment hcp consent disclose individualname transfer value result summary trial publicly available clinical trial transparency country possible local disclosure rule clinical study register introduce new mobile application enable access register mobile device effort continue reflect europe consent contract policy mean work hcp withhold consent gsk launch trial sponsor datum share platform patrick vallance publish payment receive reportable activity share access anonymise patientlevel datum sharing access outgoing president datum month publication interventional phase iiv clinical trial access datum external researcher submit research proposal review scientific merit independent review panel appoint wellcome trust read online read online sale marketing practice datum transparency european federation pharmaceutical industry association gsk study register gsk responsible business supplement rigorous patient consumer safety minimise animal testing addition continue support wide effort enhance commitment continue ensure interest safety commitment rigorously challenge need animal detection monitor understand prevention effect patient consumer paramount importance study work minimise impact animal pharmaceutical product know pharmacovigilance way design undertake clinical trial welfare invest development alternative product quality assurance monitoring continue work partner study share animalbase datum develop infrastructure report effect develop report adverse event ongoing product usage world extend access medicine vaccine transcelerate collaboration work complete promote harmonised approach procedure clinical progressing development drug implement key regulation reduce risk falsify medicine progress progress counterfeit product support revise definition substandard animal research essential discovery new medicine robust policy process ensure safety patient falsify medicine clearly categorise main require legally test safety medicine vaccine consumer clinical trial participant remain paramount type unsafe healthcare product pose important public committed apply approach replace reduce development testing manufacture medicine vaccine health issue refine animal study demonstrate respect consumer healthcare product produce responsibility animal address distribution counterfeit product collaborate follow strict quality management system manufacture custom authority prevent import export availability follow oneoff increase related integration comply regulation good manufacturing practice illicit product primary focus country counterfeit novartis vaccine business maintain longstanding recent year proactively invest quality product know manufacture know major downward trend number animal improvement programme site term facility transit hub illicit product approximately animal few previous year infrastructure way work staff training awareness rodent conduct training session custom official key result increasingly borne few supply port border crossing country work collaborate clinical expert regenerative medicine interruption improve regulatory inspection record base aim help authority identify seize shipment counterfeit university college london develop artificial human lung likeforlike comparison business unit product distribute market world enable study human respiratory pathology physiology regulatory inspection hold manufacturing site vitro work clinical oncologist bioengineer majority result zero minor observation queen mary university london develop tumour model commit addressing issue raise inspection humanrelevant tool identification innovative cancer continual improvement programme regulatory authority therapie system reduce need animal study accept propose plan corrective action mimic disease see human organ tissue understand risk past decade vaccine division work track risk quality safety standard reduce number animal need quality control purpose global risk register perform audits effort include innovative medicine initiative vaccine trial conduct party behalf datum vaccine project collaborative initiative aim reduce animal summary enhance policy management testing require batch release vaccine gsk human safety information gsk product train activity lead approval quality control test result relevant staff safeguard people product reduction number rabbit need testing clinical research read online read online pharmacovigilance use animal gsk responsible business supplement respect human right work party base initial risk assessment party commitment address guide principle commitment seek work party undergo extensive independent assessment ecovadis business human right operation share commitment high ethical standard cover management labour right fair business practice supplier relationship operate responsible way performance gap antibribery corruption environment sustainable procurement identify appropriate commit working monitor risk compliance audits party improve performance conduct party audits health safety ethic environment labour right conduct party audit focus specifically quality process progress progressing identify area require improvement engage relevant party develop improvement plan track progress progress progress significant issue identify remain unresolved choose suspend terminate work party focus activitie seven area base operation spend billion year supplier distributor big potential affect human right healthcare air quality organisation include vendor provide impact relate propellant clinical trial standard employment wide range good service continue practice patient safety product counterfeiting use thirdparty optimise increase spend preferred supplier base supplier progress outline relevant section enable build strong relationship supplier report critical business include indepth information expectation oversee party relate human right mandatory annual living value gsk party include supplier distributor training particularly relation labour right organisation transfer value party supply chain hold workshop senior manager oversight programme strengthens management risk build awareness understand labour right risk gsk supply chain driving improvement party network operation supply chain identify training ensure share value work ethical requirement team business business standard expect gsk end deploy rollout programme globally cover continue monitor exist supplier screen new supplier party expect remainder complete early party oversight programme roll globally work party standardise risk assessment party labour right clause contract party update conduct inception programme supplier portal human right policy information improvement plan agree work labour right support compliance party implement plan second annual modern slavery act statement publish line legislation outline policy process minimise risk modern slavery operation supply chain improvement plan agree inception read online party oversight programme human right statement read online modern slavery act statement ethical conduct party gsk responsible business supplement ensure ethical interaction commitment demonstrate gsk interaction register lobbying cost relate gsk activity brussels approach tax transparency register federal patient advocacy group political stakeholder lobbying register respectively cost represent substantial business employment conduct appropriately ethically transparently interest institution million presence country globe spend million lobbying activity cost include pay significant tax include operate advocacy office brussels washington corporation business taxis complete cost travel consulting industry body tax associate employee lobby indirectly behalf publish list main trade association membership website progress understand responsibility pay appropriate tax gsk corporate political contribution fully support effort ensure company appropriately transparent work patient advocacy group federal election campaign act employee financially tax affair manage provide detail engage support patient organisation gain support individual candidate political group political approach tax publish tax strategy annual report insight help develop product advocate policy action committee pac employees pac contribute approach align investment strategy well meet patient need information support candidate go state candidate country substantial economic activity provide patient group publish website federal candidate government policy promote tax regime attractive business investment transparent intent available hese late available figure figure available april hold patient advocacy leader summit czech submission eus transparency register relevant tax payer patent box republic germany japan switzerland build relationship relationship tax authority gsk employee patient advocate health policy expert seek maintain open positive relationship government industry representative tax authority worldwide welcome constructive debate launch respiratory health advisory board taxation policy representative patient organisation provide perspective international tax framework expert insight need patient allow support oecd principle tax pay develop well medicine advocate policy base supply chain profitmake activity place need support second asia pacific patient lung transfer pricing summit connect patient leader advocate lung health line oecd guidelines base transfer pricing policy community improve understand condition armslength principle support transfer price economic like asthma analysis report tax haven engage political stakeholder engage artificial tax arrangement business expect gsk follow guideline code commercial substance seek avoid tax tax haven conduct interaction stakeholder political transaction fully disclose tax authority stakeholder exception rule apply public zerotolerance approach tax evasion facilitation tax evasion policy group engage behalf comprehensive corporation tax criterion guide selection group ensure share group pay corporate income tax million value million profit million million correspond tax charge profit million million read online read online tax strategy patient group fund annual report public policy patient advocacy gsk responsible business supplement people develop people healthy employee engagement inspire workplace know listen respond protect people commitment continue create work environment people critical success reportable injury illness rate inspire people grow perform healthy hour work compare rate comparable sustainable way lead company sector remain low employee share view year global employee survey good response rate align survey question new longterm business priority innovation want prevent get hurt work help performance trust progress well identify manage risk begin analyse result valuable insight people feel work happen bad case scenario specific incident gsk engagement level increase significantly progress order improve effectiveness prevention measure survey employee recommend gsk great place work increase proud work gsk road safety remain big risk tragically member develop talent sale force die result road traffic accident employee feel particularly ethical behaviour strengthen focus identify key role effort reduce risk continue focus train quality health safety want create well business monitor talent support development gsk driver road safety opportunity development improve system process result survey discuss leader employee train people support promotion health wellbee business identify priority focus area role second line leader leader share committed provide health programme service plan survey people twice year help gauge progress knowledge helped improve colleague performance help people healthy choice assess health making coaching programme employee stop smoke physical activity eat healthily focus new engagement programme let talk aim people business skill train module suite energy matter ultimately want feel talk matter encourage share different training leadership programme develop talent gsk healthier happy energise work home view idea gsk strong graduate postgraduate join future leader programme service leader business host conversation esprit development programme gsk rank available country cover employee globally team range topic feedback insight guardian graduate employer access easy online hub pilot session collate share employee senior leader help shape future plan organisation times graduate employer personalise interactive digital health platform belgium helps welcome apprentice canada ireland singapore employee assess health adopt healthy behaviour continue expand apprenticeship programme virgin pulse global challenge gsk participant internationally gsk vote employer take million step result name active science school leaver enter apprenticeship organisation second year run company employer list time contribute partnership prevention programme offer development national apprenticeship standard chair employee family member unprecedented access lifescience trailblazer group preventive healthcare service immunisation cancer screen little extra cost extend programme invest people critical ensure asia pacific region prepare extend europe available country complete global longterm sustainability business rollout plan year employee claire thomas family access health service senior vice president human resource programme read online base benchmarke datum pharmaceutical safety group working gsk gsk responsible business supplement promote inclusion diversity community volunteering create change woman management commitment continue promote inclusion diversity commitment extend volunteering opportunity bring globally gsk svpvp positive change communitie global health director provide individual development manager progress total complete progress global lgbt council continue engage people gsk lgbt issue support lgbt erg progress independent hampton alexander review ftse spectrum employee member company find gsk eighth high proportion country world skillsbase volunteering people opportunity woman board line support community global health build ftse average female representation achieve mark human right campaign ability experience executive committee member direct report corporate equality index second consecutive year well good award inclusion volunteer country take flagship proportion woman management role gsk national business inclusion consortium lgbt chamber pulse volunteer partnership programme total provide globally provide coach support highperforming commerce achieve rainbow tick certification new zealand million worth skilled service nonprofit partner female manager accelerate difference programme early rank stonewall workplace country start programme equality index list lgbt inclusive pulse individual work nonprofit organisation promote begin compare employer month share expertise learn new skill woman man gsk period new singapore asia headquarters design fully late survey pulse programme volunteer woman new graduate esprit participant accessible people disability develop completing assignment agreed bring new apprentice science technology inclusive design guide future building refurbishment new idea fresh way work gsk nonprofit partner engineering role woman traditionally introduce service easy benefit agree volunteer meet underrepresented additionally women leadership initiative employee request workplace adaptation flexible exceed expectation employee resource group erg employee work assistive technology furniture access service gsk opportunity volunteer day member country roll country year year support local community orange day new legislation publish datum gender pay disability confidence network erg skillsbase volunteering opportunity october gap time base comparison salary employee member country support global people contribute hour global gender pay gap gsk permanent ukbased employee disability council driving change promote disability month volunteering mean national average confidence business continue review pay equity global level young people learn disability develop currently seven nationality represent board employment skill project search programme executive committee seventyeight nationalities represent operate orange future leader graduate programme people senior programme employ people disability hour contribute people complete emerge leader programme singapore age japan global month volunteering develop asia leadership pipeline read online inclusion diversity read online gender pay gap report employee volunteering gsk responsible business supplement planet aim carbon neutral scope greenhouse gas emission thousand tonne coe indirect emission commitment reduce overall carbon footprint scope emission fall million tonne coe carbon neutral value baseline chain year result novartis integration increase sale propellantbase inhaler engage supplier drive improvement example encourage supplier monitor work need disclose performance ecodesk external resource offer benchmarke information help develop improvement plan supplier represent billion spend progress raw material use ecodesk report environmental datum overall value chain carbon footprint scope platform encourage supplier emission direct operation scope emission share good practice sustainability gsk supplier exchange supplier base use product recognise outstanding performance annual supplier environmental sustainability awards award go provide medicine vaccine consumer healthcare paharpur small packaging supplier india effort product people need world target reduce water use model large packaging supplier prove extremely challenging reduce overall value installation paper recycling facility site switzerland electricity steam propellant emission chain footprint gas fuel manufacture inhaler late analysis show total value chain carbon footprint use product significant impact scope sale force travel emission emission majority patient use propellantbase estimate million tonne coe inhaler ventolin propellant greenhouse gas release reduction compare baseline value chain footprint increase use reduce impact propellant complex scope greenhouse gas emission thousand tonne continue research feasible solution issue include operation change way manufacture reduce operational emission scope reduce propellant maintain efficacy safety patient compare previous year result continue gsk new generation inhaler product ellipta device focus energy efficiency measure purchase renewable develop launch dry powder inhaler dpis energy baseline reduce annual carbon release greenhouse gas emission certify emission energy use save cumulative million assessment respiratory inhaler portfolio carbon trust tonne coe show lifecycle carbon footprint dpi time lower propellantbase inhal month treatment global healthcare company recently available scope datum contribute tackle month treatment dose propellant inhaler carbon footprint effect cause climate change rbkg ooe rie oar erit dose daily ellipta dpi roger connor president global manufacturing supply target purchase good service product product logistic disposal product business travel air commuting emission read online propellant emission aim carbon neutral use inhaler gsk responsible business supplement reduce water impact reduce waste commitment reduce water impact value commitment reduce operational waste waste water pollution supply chain chain risk pharmaceutical particularly antibiotic enter environment waste water pollution progressing track grow concern active area research gsk antimicrobial resistance amr industry alliance launch progress progress signatory industry roadmap progress combat amr continue seek way use water operation cut operational waste produce robust control manufacturing supply chain use product reduce hazardous waste nonhazardous waste work supply chain partner audit compliance water use water use increase progress target slow share good practice manage environmental discharge drive growth vaccine business waste produce remain year read amr effort online increase focus reclaim waste example south africa cut water use beneficial use reuse recycling recovery example month site cape town run campaign include redistribute consumer product close expiry date encourage employee save water work home sell waste gelatine capsule production drought pilot campaign utility company paintball manufacturer poland encourage consumer turn tap brushing tooth site worldwide achieve zero waste water use water impact landfill tonne operational waste water value chain end landfill waste send landfill story measure overall water impact different recycled incinerate recover energy category water scarcity local water quality health social risk regulatory reputational risk end pharmaceutical consumer healthcare manufacturing site complete water risk assessment category line water stewardship standard site process develop plan address risk site worldwide achieve identify include situation zero waste landfill work local community stakeholder effort enhance water stewardship prioritise site area water stress address impact waterstresse region india value chain horlick make entire value chain water footprint globally past year assess milk malt wheat supplier india understand water impact implement project recharge water year read online water stewardship policy read online reduce water impact reduce waste gsk responsible business supplement engage stakeholder welcome insight stakeholder relationship example listen engage external stakeholder help well understand listen people global employee survey respond feedback employee expectation identify societal listen respond people help promote dialogue ask idea let talk trend inform approach maintain strong employee engagement retain communicating regular update purpose strategy progress live broadcast talented people session message ceo member corporate executive team responsible business phil thomson government multilateral president global affairs drive progress key global health priority area world health assembly organisation join coalition focus end pneumonia death child interact government policymaker work government nhs establish future life sciences engage stakeholder play follow clear transparent standard advocate sector post brexit policy encourage innovation promote partner key stakeholder develop vaccine procurement mechanism humanitarian key development new efficient management healthcare spending setting longterm priority innovation performance patient support need trust provide example engage key stakeholder group investor link information specific communicate strategy responsible run investor roadshow conference event gskcom engagement outcomes business approach performance investor hold onetoone meeting individual investor include sris community include socially responsible investor respond investor survey dow jones sustainability index djsi sris channel partner nonprofit implement programme strengthen healthcare infrastructure ngo local community support people live hiv viiv healthcare positive action programme work partner strengthen work malaria comic relief advocate government healthcare infrastructure improve malaria summit commonwealth head government meeting access healthcare global working save child combine expertise resource influence reduce local community programme child mortality patient group healthcare run patient advocacy leader summit professional set advisory board representative patient organisation provide financial support patient group disclose website engage support patient organisation gain insight enable develop product online resource inhouse medical capability provide information medicine advocate policy well meet patient need vaccine healthcare professional want communicate value expectation responsible business supplier portal supplier party share good practice support improvement environmental performance aim build strong relationship supplier exchange supplier party engage supplier social environmental performance party share value oversight programme external platform ecovadi ecodesk gsk responsible business supplement datum summary health well access number dose synflorix vaccine supply gavi million medicine vaccine number dose rotarix vaccine supply gavi million value gsk medicine vaccine prescribe patient assistance programme cost good sell million usd number patient reach patient assistance programme community investment cash million product inkind million time million management cost million strengthen healthcare health worker training programme million infrastructure health worker partner train cumulative number people reach reinvestment programme million cumulative neglect tropical disease albendazole tablet help lymphatic filariasis elimination million albendazole tablet help treat intestinal worm million eradicating polio number dose oral polio vaccine deliver global polio eradication initiative million behaviour compliance employee discipline policy violation employee dismiss agree leave company voluntarily document warning total number market promotional activity violation number contact speak channel clinical trial datum publicly available trial result summarie cumulative number study clinical study report post register number trial list patient level datum available request number research team approve access gsk trial datum figure include healthwork programme develop country ldc programme figure include project relate novartis asset project fully transition novartis figure exclude project relate novartis project gsk responsible business supplement behaviour clinical research audits investigator site audits gsk process audits gsk local operating company investigation suspect irregularity audits contract research organisation total audit undertake anticounterfeite number training custom official ensure quality manufacture number regulatory inspection pharmaceutical business supply number regulatory inspection vaccine business number regulatory inspection consumer healthcare business people health safety number fatality reportable incident lose time lose time reportable injury illness rate reportable incident lose time reportable injury illness rate talent leadership development total number coach assignment number graduate recruit future leader programme number postgraduate recruit esprit programme number apprentice recruit inclusion diversity percentage woman management total volunteering number employee complete pulse health safety datum restate include novartis site acquire gsk responsible business supplement planet carbon scope ghg emission tonne coe gas fuel electricity steam propellant emission manufacture inhaler sale force travel emission total scope ghg emission tonne coe purchase good service product logistic business travel air commute propellant emission use inhaler use product disposal product emission total water water use operation million cubic metre waste total waste generate thousand tonne waste landfill thousand tonne compliance internal audits number environmental fine environmental remediation spend million propellant emission datum collect internal system accurate picture scope ghg emission later year detailed breakdown environmental fine available responsible business supplement fine discovery waste tank upper merrion site comply local regulation plus fine pay hamilton site failure submit risk management plan storage use chloroform responsibility remove pollution contaminant soil surface ground water facility previously disposal site waste management company gsk responsible business supplement reporting report performance annually report commitment open transparent business activity responsible business cover annual report datum coverage feedback count datum report relate gsk global operation welcome feedback responsible business calendar year state datum performance report request receive contribute global goal environment health safety section independently regular update progress verify dnv brand name appear italic summary assurance statement gsk opportunity significant contribution report trade mark own license gsk independent assurance provider dnv provide sustainable development goal sdgs associate company limit assurance accordance assurance standard fully commit expertise experience reporting standard isae revise assurance scope include select support late materiality assessment index global reporting initiative guideline show ehs performance datum disclose page sdgs key input element cover report signatory responsible business supplement lead global healthcare business global compact publish annual communication dnv gls statement include assurance conclusion big difference sdg ensure healthy life progress demonstrate uphold principle summary work perform find website promote wellbee particular key target available gskcom contact csrcontactgskcom sdg achieve universal health coverage portfolio policy code standard alongside commitment access innovation flexible number policy code standard accessible pricing clearly support target website cover range different area public health business integrity environment find aim contribute sdgs download include gender equality good job economic growth environmental challenge read online public policy sdgs sdg factsheet